AbbVie stays bullish on future performance as Skyrizi continues to impress — but 'price controls' would be a game changer - Endpoints News

AbbVie’s executive team stayed right on track in Q2, with its Skyrizi franchise — now newly approved for Crohn’s — continuing to rack up impressive sales, making up for some unexpected weakness from a stronger dollar. The erosion of the Imbruvica franchise, h…

Make way, Dermavant. Two months after the company vowed to upend the plaque psoriasis market with its newly approved vanishing cream, there’s another topical to contend with. Arcutis Biotherapeutics… [+704 chars]

full article...